Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Positive 67.9%

Neg 0% Neu 0% Pos 67.9%

Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.